[HTML][HTML] Electronic nose and its applications: A survey

D Karakaya, O Ulucan, M Turkan - International journal of Automation and …, 2020 - Springer
In the last two decades, improvements in materials, sensors and machine learning
technologies have led to a rapid extension of electronic nose (EN) related research topics …

[HTML][HTML] Bloodstream infections in critically ill patients: an expert statement

JF Timsit, E Ruppé, F Barbier, A Tabah… - Intensive care medicine, 2020 - Springer
Bloodstream infection (BSI) is defined by positive blood cultures in a patient with systemic
signs of infection and may be either secondary to a documented source or primary—that is …

[HTML][HTML] Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO …

RG Wunderink, EJ Giamarellos-Bourboulis… - Infectious diseases and …, 2018 - Springer
Methods A total of 77 patients with confirmed/suspected CRE infection (bacteremia, hospital-
acquired/ventilator-associated bacterial pneumonia, complicated intra-abdominal infection …

[HTML][HTML] Bacteriophage therapy: clinical trials and regulatory hurdles

LL Furfaro, MS Payne, BJ Chang - Frontiers in cellular and infection …, 2018 - frontiersin.org
Increasing reports of antimicrobial resistance and limited new antibiotic discoveries and
development have fuelled innovation in other research fields and led to a revitalization of …

[HTML][HTML] Fighting antibiotic resistance in hospital-acquired infections: current state and emerging technologies in disease prevention, diagnostics and therapy

E Avershina, V Shapovalova, G Shipulin - Frontiers in microbiology, 2021 - frontiersin.org
Rising antibiotic resistance is a global threat that is projected to cause more deaths than all
cancers combined by 2050. In this review, we set to summarize the current state of antibiotic …

[HTML][HTML] The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how

I Karaiskos, S Lagou, K Pontikis, V Rapti… - Frontiers in public …, 2019 - frontiersin.org
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …

A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital …

I Titov, RG Wunderink, A Roquilly… - Clinical Infectious …, 2021 - academic.oup.com
Background Imipenem combined with the β-lactamase inhibitor relebactam has broad
antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We …

Epidemiology of carbapenem-resistant Gram-negative infections globally

AJ Brink - Current opinion in infectious diseases, 2019 - journals.lww.com
High-resistance rates in carbapenem-resistant GNB in many countries will inevitably
complicate treatment of serious infections in vulnerable patient groups and should …

[HTML][HTML] The cGAS-STING pathway in bacterial infection and bacterial immunity

N Liu, X Pang, H Zhang, P Ji - Frontiers in immunology, 2022 - frontiersin.org
Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP)(cGAMP)
synthase (cGAS), along with the adaptor stimulator of interferon genes (STING), are crucial …

Analysis of the clinical antibacterial and antituberculosis pipeline

U Theuretzbacher, S Gottwalt, P Beyer… - The Lancet Infectious …, 2019 - thelancet.com
This analysis of the global clinical antibacterial pipeline was done in support of the Global
Action Plan on Antimicrobial Resistance. The study analysed to what extent antibacterial …